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Background and purpose: We aimed to determine the prevalence of epilepsy in
patients with multiple sclerosis (MS) at diagnosis, the risk of developing epi-
lepsy after the diagnosis of MS and the relative risk of mortality associated
with epilepsy.
Methods: We used the UK Clinical Practice Research Data-link to identify
2526 patients with incident MS and 9980 age-, sex- and index year-matched
non-MS controls from 1997 to 2006. Logistic regression was used to estimate
odds ratios [95% conﬁdence interval (CI)] for epilepsy and Cox regression was
used to estimate hazard ratios (HRs) (95% CI) for epilepsy and mortality.
Results: Patients with incident MS were on average 45 years old and 70.9%
were female. At diagnosis, the prevalence of epilepsy in patients with MS was
1.30% compared with 0.57% in non-MS controls. At diagnosis, MS was asso-
ciated with an adjusted odds ratio (95% CI) of 2.11 (1.36–3.27) for pre-exist-
ing epilepsy. Among epilepsy-free patients, the cumulative probabilities of
developing epilepsy, ﬁrst recorded within 10 years of the index date, were
2.77% for patients with MS and 0.90% for controls. MS was associated with
an adjusted HR (95% CI) of 6.01 (2.94–12.29) for epilepsy. Among patients
with MS, epilepsy was associated with an HR (95% CI) of 2.23 (1.02–4.84)
for all-cause mortality.
Conclusions: This population-based study found an increased prevalence of
epilepsy in patients with MS at diagnosis when compared with non-MS con-
trols and the risk of developing epilepsy was also higher following the MS
diagnosis. Patients with MS with epilepsy had a higher risk of mortality com-
pared with those without.
Introduction
Multiple sclerosis (MS) is a female-predominant cen-
tral nervous system inﬂammatory demyelinating dis-
ease that is associated with multiple comorbidities and
increased mortality [1,2]. Epilepsy is one of the
comorbidities in patients with MS that is more
common than in the general population [1,3,4], which
may lead to lost years of life [5]. However, Finnish
and Canadian studies did not document the associa-
tion between epilepsy and increased mortality in
patients with MS [1,4].
Epileptic seizures involve excessive and hypersyn-
chronous cortical brain network electrical activity,
and therefore cortical and subcortical lesions in MS
potentially contribute to an increased risk of epilepsy
in MS [6,7]. The pathogenesis has not been clariﬁed.
Previous studies found an earlier disease onset of MS
in patients with epilepsy compared with those without
epilepsy [8]. However, it is not completely conclusive
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as to how epilepsy modiﬁes the clinical course of MS
[9]. It is also possible that epilepsy has an eﬀect on
brain atrophy that is additive to that of MS and thus
contributes to a more rapid progression [8].
We hypothesized that patients with MS had a higher
risk of epilepsy at and after diagnosis and that epilepsy
in patients with MS increased mortality. Using data
representative of the UK general population from the
Clinical Practice Research Data-link (CPRD), we esti-
mated the prevalence of epilepsy at the time of the MS
diagnosis compared with matched controls in a pri-
mary care setting. We further followed patients with
incident MS and their matched controls after initial
MS diagnosis to compare their subsequent risks of
developing epilepsy. Furthermore, we compared mor-
tality in patients with MS with and without epilepsy.
Methods
The study was approved by the Independent Scientiﬁc
Advisory Committee for the Medicines and Health-
care products Regulatory Agency Database Research
(protocol 14-070).
Data source
The CPRD is a primary care database in the UK that
contains prospectively collected medical records of
research standards from around 16.5 million individu-
als registered in over 701 general practices [10]. The
validity of the diagnoses recorded in the database is
high, with conﬁrmation of diagnoses in a median of
89% for 183 diﬀerent conditions [11].
Study population
Our source population comprised all participants who
contributed data to the CPRD between 1 January 1997
and 31 December 2006. We used Read codes (Table S1)
to identify patients with MS, which have been used [2]
and validated [12] previously. Patients with incident MS
were participants with no evidence of MS prior to the
time of diagnosis (assigned as the index date) and with
at least a 3-year continuous registration prior to the
index date [12,13]. The case deﬁnition was based on
physician diagnosis using Read codes. Hernan et al. [12]
reported that 91.8% of patients with a MS diagnosis in
the CPRD were conﬁrmed or possible cases of MS after
a thorough chart review.
Selection of controls
Matched controls were selected from people who had
an active registration in 1997–2006 and had no MS
diagnosis. For each patient with MS, four randomly
selected controls were matched by year of birth
(2 years), sex, general practice and year of ﬁrst con-
tinuous registration (2 years) (Fig. 1). The same
index date was assigned to matched controls. As with
patients with MS, there must have been 3 years of
continuous registration prior to the index date.
Study period
We deﬁned two periods to assess epilepsy: (i) the
10 years prior to diagnosis and (ii) from diagnosis to
the earliest date of occurrence of the diagnosis of epi-
lepsy, death, transfer out, last data collection time for
practice or end of study (30 June 2016), whichever
came ﬁrst (Fig. S1).
Definition of epilepsy
We developed the Read code lists of epilepsy
(Table S2) based on the opinions of two senior neu-
rologists and a general practitioner. We were unable
to validate epilepsy diagnosis in this study. However,
epilepsy is an established paid-for-performance indica-
tor for general practices in the UK to improve quality
of care [14] and decrease mortality [15]. We performed
sensitivity analyses by using an alternative case deﬁni-
tion based on Read codes plus a prescription of
antiepileptic drugs (AEDs).
We performed two sensitivity analyses. One
included AEDs that were used by >1% of patients
with epilepsy in the UK according to a previous
CPRD study. The included AEDs were valproate, car-
bamazepine, lamotrigine, phenytoin, levetiracetam,
phenobarbital, clobazam, topiramate, gabapentin,
clonazepam, primidone and pregabalin [16]. The other
included the aforementioned AEDs except for gaba-
pentin and pregabalin, as both are more often pre-
scribed for pain than for epilepsy.
Mortality
Mortality was based on the recording in the main
database. The CPRD has an algorithm to identify
death and date of death of participants. We have pre-
viously validated the recorded death in the CPRD
main database [17]. The recording of death and death
date in the CPRD is generally consistent with the
national death registration.
Covariates
Covariates included general characteristics [age, sex,
body mass index (BMI)], lifestyle factors (smoking status
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and alcohol consumption) and Charlson comorbidity
index, which were derived from 17 diagnostic categories
(Table S3) [18,19]. BMI, smoking and alcohol consump-
tion have been recognized as potentially modiﬁable fac-
tors aﬀecting MS risk [20–22] and possibly epilepsy [23–
25]. The deﬁnition of these categories was based on physi-
cian diagnoses recorded as a list of Read codes [18,26].
Statistical analysis
The prevalence of epilepsy at index date was calculated
by dividing the number of people diagnosed with epi-
lepsy before the index date (numerator) by the number
of patients with incident MS or non-MS controls (de-
nominators). Odds ratios (ORs) and 95% conﬁdence
interval (CI) were used to estimate the association
between MS and epilepsy at index date using condi-
tional logistic regression adjusting for age, sex, index
year, BMI category, smoking status, alcohol consump-
tion and Charlson comorbidity index. Missing data for
BMI, smoking and alcohol status were coded as ‘un-
known’. Kaplan–Meier plots were used to estimate the
probability of epilepsy in people with incident MS and
those without MS at and following diagnosis. The log-
rank test was used to compare the probability of epi-
lepsy between patients with MS and controls. Only
people at risk for epilepsy (not having epilepsy at index
date) were considered to estimate the hazard ratios
(HRs) for developing epilepsy. HRs and 95% CI were
calculated for incident epilepsy using a Cox propor-
tional hazards model. The HRs were adjusted for age,
sex, index year, BMI categories, smoking status, alco-
hol consumption and Charlson comorbidity index.
To examine the eﬀect of epilepsy on death among
patients with MS, we limited the analyses to those with
MS. Patients with MS were followed from the index
date. We considered epilepsy as a time-varying factor.
Those with epilepsy at or prior to diagnosis and those
without epilepsy through follow-up were followed from
the diagnosis to the censor date (the earliest date of
occurrence of death, transfer out, last data collection
time for the practice or end of study, i.e. 30 June 2016).
Patients with MS who developed epilepsy after the diag-
nosis of MS had their follow-up divided into two parts:
non-epilepsy exposure and epilepsy exposure. Non-epi-
lepsy exposure period was deﬁned as from MS diagnosis
to the censor date. Epilepsy exposure period was deﬁned
as from the ﬁrst date when epilepsy was diagnosed to
the censor date. All statistical analyses were performed
using SAS statistical software, version 9.3 (Marlow,
Buckinghamshire, UK).
Results
We identiﬁed 2526 patients with incident MS from
1997 to 2006 with a mean age of 45.0  12.4 years
(70.9% female). The median observation period (in-
terquartile range) was 12 (7–21) and 10 (5–13) years
before and after the index date, respectively. They
were matched to 9980 controls with similar age and
sex structure and observation periods before and after
their index dates (Table 1).
Retrospective observation
On the index date, 33 patients with MS (21 females)
already had an epilepsy diagnosis, equivalent to a
prevalence of epilepsy of 1.30% (95% CI, 0.90%–
1.83%). We also identiﬁed 57 controls with epilepsy
(38 females), with a signiﬁcantly lower prevalence of
Patients with MS in 1997–2006 
(n = 2531)
At least a 3-year continuous registration 
prior to the index date
Individuals with active registration in 
1997–2006 (n = 9 335 073)
Only people with no evidence of MS
1. We selected people with at least a 3-year 
continuous registration prior to the index 
date
2. Matched cases 1:4 with controls, by 
year of birth, gender, general practice and 
year of first continuous registration in 
CPRD
Matched cases (n = 2526) Matched controls (n = 9980)
Figure 1 Flowchart of eligible patients
with multiple sclerosis (MS) and
matched controls. The study comprised
patients with incident MS each with four
matched non-MS controls who were
continuously registered for at least
3 years before the date that MS was ﬁrst
recorded during 1997–2006. CPRD,
Clinical Practice Research Data-link.
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0.57% (95% CI, 0.43%–0.74%; P < 0.0001). In a
logistic regression model adjusting for age, index year,
BMI, smoking, alcohol consumption and Charlson
comorbidity index, MS was associated with an OR of
2.11 (95% CI, 1.36–3.27) for epilepsy.
Follow-up data after the index date
Figure 2 compares the cumulative probability of ﬁrst
recorded epilepsy between patients with MS and matched
controls who were epilepsy-free at index date (log-rank
test, P < 0.001). The cumulative probabilities of ﬁrst
recorded epilepsy at 1, 5 and 10 years from index date
were 1.46%, 2.07% and 2.77% in patients with incident
MS and 0.65%, 0.78% and 0.90% in controls.
Next, we investigated the relative risk of incident
epilepsy diagnosis in patients with MS compared with
non-MS controls. Using Cox proportional hazard
model adjusting for age, index year, BMI, smoking,
alcohol consumption and Charlson comorbidity index,
MS was associated with an HR (95% CI) of 6.01
(2.94–12.29) for epilepsy (Table 2).
Mortality
We limited the analysis to patients with MS to exam-
ine the association between epilepsy and all-cause
mortality. After controlling for BMI group, Charlson
comorbidity, smoking and alcohol use, epilepsy was
associated with an HR of 2.23 (95% CI, 1.02–4.84)
for all-cause mortality in patients with MS.
Sensitivity analysis
Using the alternative case deﬁnition of epilepsy (a
diagnosis plus a prescription of AEDs), we identiﬁed
31 patients with MS who already had epilepsy, equiv-
alent to a prevalence of epilepsy of 1.23% (95% CI,
0.84%–1.74%) and 44 controls who already had epi-
lepsy, with a signiﬁcantly lower prevalence of 0.44%
(95% CI, 0.32%–0.59%; P < 0.0001). Using a logistic
regression model, MS was associated with an adjusted
OR (95% CI) of 2.40 (1.37–4.22). Among those with-
out epilepsy at baseline, 31 patients with MS and 20
controls developed epilepsy after the index date. Using
Cox proportional hazard model, MS was associated
with an adjusted HR of 6.79 (95% CI, 3.78–12.18).
In the second set of sensitivity tests using the case
deﬁnition of epilepsy with a diagnosis plus a prescrip-
tion of AEDs excluding gabapentin and pregabalin,
we identiﬁed 28 patients with MS who already had
epilepsy, equivalent to a prevalence of epilepsy of
1.11% (95% CI, 0.74%–1.60%) and 43 controls who
already had epilepsy, with a signiﬁcantly lower
Table 1 Characteristics of patients with incident multiple sclerosis (MS) and matched non-MS controls
Characteristic Incident MS (n = 2526) Non-MS controls (n = 9980) Adjusteda OR (95% CI)
Age (years) (SD) 45.04  12.37 45.17  12.43
Female gender 1790 (70.9) 7070 (70.8)
Median observation (years) (IQR)
Prior to index date 12 (7–21) 12 (7–20)
After index date 10 (5–13) 10 (6–13)
BMI (kg/m2)
<25.0 1052 (41.65) 3621 (36.28) Reference
25.0–29.9 685 (27.12) 2670 (26.75) 0.88 (0.79–0.98)*
≥30 469 (18.57) 1871 (18.75) 0.86 (0.76–0.97)*
Unknown 320 (12.67) 1818 (18.22) 0.57 (0.49–0.66)*
Smoking
Non-smoker 720 (28.5) 2953 (29.59) Reference
Current smoker 554 (21.93) 1542 (15.45) 1.53 (1.34–1.75)*
Ex-smoker 878 (34.76) 3261 (32.68) 1.09 (0.97–1.24)
Unknown 374 (14.81) 2224 (22.28) 0.62 (0.54–0.72)*
Alcohol consumption (units/week)
Never/ex-drinker 333 (13.18) 1085 (10.87) Reference
Current 1–9 1245 (49.29) 4523 (45.32) 0.90 (0.78–1.03)
Current ≥10 344 (13.62) 1321 (13.24) 0.83 (0.68–1.01)
Unknown 604 (23.91) 3051 (30.57) 0.59 (0.50–0.70)*
Charlson comorbidity index
0 1952 (77.28) 8303 (83.2) Reference
1–2 501 (19.83) 1518 (15.21) 1.42 (1.27–1.60)*
≥3 73 (2.89) 159 (1.59) 1.99 (1.49–2.66)*
BMI, body mass index; CI, conﬁdence interval; IQR, interquartile range; OR, odds ratio. Data are given as n (%) unless stated otherwise.
*P < 0.05. aAdjusted for age, sex and index year.
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prevalence of 0.43% (95% CI, 0.31%–0.58%;
P < 0.0001). MS was associated with an adjusted OR
(95% CI) of 2.37 (1.33–4.24). Among those without
epilepsy at baseline, 31 patients with MS and 16 con-
trols developed epilepsy after the index date. Using
Cox proportional hazard model, MS was associated
with an adjusted HR of 8.64 (95% CI, 4.63–16.09).
Discussion
This population-based study found that approximately
one in 80 patients with incident MS already had epi-
lepsy at diagnosis, which is twice as many as for con-
trols. After 10 years of follow-up, 2.77% of epilepsy-
free patients with MS at diagnosis were diagnosed
with epilepsy. MS was associated with a sixfold risk
of epilepsy. Furthermore, our results documented a
twofold increase in the risk of mortality in patients
with MS with epilepsy compared with those without.
Overall, epilepsy is not uncommon in patients with
MS and is a poor prognostic factor for death.
A recent systematic review summarized data from
24 studies and estimated that the prevalence of seizure
disorders in patients with MS ranged from 0.89% to
8.06% with a high heterogeneity among studies [27].
Several studies reported a comparison of epilepsy risk
in patients with MS and controls. In general, the risk
ratio between MS and controls ranged from 1 to 16
[27–29]. Allen et al. [30] found that patients with MS
have a three- to fourfold higher risk of hospital
admissions for epilepsy than other patients without
MS. The current study found that patients with inci-
dent MS have a sixfold risk for epilepsy, which may
not need admission, compared with controls using the
CPRD.
Several studies estimated the incidence of epilepsy
in patients with MS. For example, the cumulative
incidence of epilepsy in the Swedish MS register has
an increasing trend after MS diagnosis compared with
controls [3]. The current study utilized data from the
CPRD, which is representative of the primary care
population in the UK, to ensure a minimum selection
bias. In addition to sex and age, we further matched
by factors such as the comorbidity index and lifestyle
factors, which are relevant to both MS and epilepsy
[18,20–26]. In addition, our design considered the tim-
ing of both MS diagnosis and epilepsy onset. We
found that patients with MS already had a higher risk
of epilepsy at the time of diagnosis and the risk was
also higher after the diagnosis. Our ﬁndings support
that the concurrence of MS and epilepsy is not a
chance association, but rather that epilepsy is an inte-
gral part of MS.
The pathogenesis of epilepsy in MS remains elusive.
Thompson et al. [31] reported seven patients with MS
with acute seizures whose magnetic resonance imaging
data revealed new evolving or enhancing lesions
involving the cortex or subcortical areas. Acute sei-
zures may remit as the oedema associated with the
lesion resolves, whereas recurrence of seizures may be
due to the damaged cerebral structures becoming
epileptogenic [31]. The hypothesis that epilepsy is
Figure 2 Cumulative probability of ﬁrst recorded epilepsy in
patients with multiple sclerosis (MS) (red) and non-MS controls
(blue). Cumulative probability of ﬁrst recorded epilepsy is higher
in patients with incident MS than in matched controls (log-rank
test, P < 0.001).
Table 2 Cox proportional hazard models examining relative risks of
the ﬁrst recorded epilepsy in patients with incident multiple sclerosis
(MS) compared with matched controls
Variable
Crude HR
(95% CI)
Adjusteda HR
(95% CI)
MS 4.53 (2.66–7.72)* 6.01 (2.94–12.29)*
BMI (kg/m2)
<25.0 Reference Reference
25.0–29.9 2.31 (1.20–4.46)* 4.83 (1.90–12.27)*
≥30 1.24 (0.53–2.91) 1.73 (0.56–5.30)
Unknown 0.65 (0.19–2.21) 2.49 (0.50–12.53)
Smoking
Non-smoker Reference Reference
Current
smoker
0.53 (0.24–1.17) 0.58 (0.20–1.64)
Ex-smoker 0.76 (0.31–1.83) 0.76 (0.21–2.73)
Unknown 0.25 (0.09–0.70)* 0.10 (0.02–0.51)*
Alcohol consumption (units/week)
Never/
ex-drinker
Reference Reference
Current 1–9 0.92 (0.38–2.26) 0.58 (0.16–2.08)
Current ≥10 1.17 (0.52–2.65) 0.79 (0.24–2.59)
Unknown 0.52 (0.19–1.38) 1.39 (0.54–3.56)
Charlson comorbidity index
0 Reference Reference
1–2 2.20 (1.04–4.65)* 3.69 (1.31–10.44)*
≥3 3.97 (1.13–13.88)* 3.66 (1.00–13.36)
BMI, body mass index; CI, conﬁdence interval; HR, hazard ratio.
Data are given as n (%) unless stated otherwise. *P < 0.05. aAd-
justed by age, sex, registered general practitioner and index year.
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associated with focal cortical and subcortical lesions
in MS is further supported by recent magnetic reso-
nance imaging studies [32–34]. Patients with MS with
epilepsy had a higher load of cortical or subcortical
lesions than 26 matched patients with MS without epi-
lepsy [32–34]. A previous study also showed that
patients with MS with epilepsy have a higher disabil-
ity score than those without epilepsy after the same
disease duration [35], which suggests the eﬀect of MS
severity on the development of epilepsy. The mecha-
nism whereby some of the MS lesions become epilep-
togenic is unknown. A recent histopathological study
showed decreased immunostaining of Kir4.1 proteins
in acute demyelinating and chronic active demyeli-
nated lesions of the subcortical regions in MS [36].
The Kir4.1 proteins are part of potassium channels
present on oligodendrocytes and loss of function of
these channels increases seizure susceptibility [37].
The long-term prognosis of patients with MS with
epilepsy compared with those without epilepsy was
not known previously. The patients with relapsing-
remitting MS with epilepsy had a more pronounced
cognitive decline and a higher disability over 3 years
than those without [34]. Among the whole MS popu-
lation, disease duration and disability score were asso-
ciated with epilepsy [3]. Gasparini et al. [35]
conducted a systematic review and revealed that the
age at onset is younger and disability score tends to
be higher in patients with MS with epilepsy than those
without. This study further found an association
between epilepsy and increased mortality in patients
with MS.
There are several limitations to this study. First, we
could not classify the disease subtypes and severity of
MS because this information was not routinely
recorded. The life expectancy in patients with MS is
related to MS itself and is correlated with disease dis-
ability severity and duration [38]. Patients with MS
with epilepsy tend to have a higher disability than
those without epilepsy [35]. In addition, the severity
of epilepsy (e.g. status epilepticus) can contribute to
early death, but this was not considered separately
because of the low number of cases. In this study, we
used the mortality outcome as a surrogate to evaluate
the eﬀect of epilepsy on the clinical course of MS.
Secondly, misclassiﬁcation bias may occur as the iden-
tiﬁcation of patients with MS was based on physician
diagnosis, rather than according to accepted criteria.
However, the diagnosis of MS in the CPRD has been
investigated and validated previously [12]. Similarly,
there may have been some misclassiﬁcation of epi-
lepsy. However, we performed a sensitivity analysis
for those with epilepsy diagnosis and found similar
results. Thirdly, the models did not adjust for all
potential risk factors for epilepsy, such as previous
head injuries or history of epilepsy in childhood.
However, part of these risk factors was accounted for
by the Charlson comorbidity index, as it incorporated
17 diﬀerent categories of illnesses. In addition, with
such a large eﬀect size of 4, it is unlikely that any or
all of these potential sources of bias explain our ﬁnd-
ings thoroughly. Furthermore, limited evidence sug-
gests that some disease-modifying treatments and
symptomatic treatments may increase the risk of
developing epilepsy [39]. We did not examine the use
of disease-modifying treatments in this cohort because
disease-modifying treatments are given in secondary
care and data on their use are not linked in the cur-
rent dataset.
Conclusion
A fraction of patients with MS (approximately 1%) in
the UK already have epilepsy at diagnosis. In epi-
lepsy-free patients, the risk of incident epilepsy was
also higher after diagnosis, aﬀecting almost a further
3% by 10 years. Patients with MS with comorbid epi-
lepsy had a higher risk for mortality than those with-
out epilepsy.
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